National Plan for Epilepsy Act
Summary
S.494, the National Plan for Epilepsy Act, is an early-stage coordination bill with zero authorized spending. It creates an advisory council and mandates federal research coordination for epilepsy but appropriates no funds. Market impact is negligible — no direct revenue driver for any public company.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.494 authorizes zero spending — it is purely a coordination-and-reporting bill.
- 2.Market impact is near zero; no company sees a direct revenue change from this legislation.
- 3.The true pure-play epilepsy company (UCB S.A./$UCBJY) is not represented in the provided market data; the $UCB data provided is for a regional bank.
Market Implications
There are no material market implications from S.494 in its current form. The bill authorizes no funding and alters no commercial incentives. UCB S.A. (OTC: $UCBJY) has the most structural exposure to epilepsy drug development, but this bill does not change its revenue outlook. Broader pharma (PFE, LLY, ABBV, VRTX) are unaffected. The provided market data shows $PFE at $26.71 (30-day -4.91%), $LLY at $920.60 (30-day +0.09%), $ABBV at $213.05 (30-day -2.05%), and $VRTX at $428.21 (30-day -4.1%) — these moves are driven by company-specific factors and broader market dynamics, not by this bill.
Full Analysis
S.494 was introduced on February 10, 2025, in the 119th Congress by Sen. Schmitt (R-MO) and has 19 cosponsors. It was referred to the Senate HELP Committee. The bill requires HHS to establish a National Plan for Epilepsy and an advisory council, coordinating research and services across federal agencies. Critically, the bill authorizes zero dollars in spending — it is a policy-and-coordination-only bill. An identical companion bill (HR1189) has been introduced in the House but likewise remains in committee.
The money trail is straightforward: there is no money. Authorization without appropriation means no new federal grants, contracts, or procurement commitments flow to any private company. The bill's provisions sunset on December 31, 2035, but without any funding mechanism, the plan exists only as a reporting and coordination framework.
Structural winners and losers: UCB remains the most directly exposed U.S.-traded pure-play in epilepsy, with Briviact and Vimpat generating significant revenue. However, the bill does nothing to change prescribing patterns, pricing, or patient access. Broader CNS pharma players like Vertex (exondysio? no — VX-548 for pain, not epilepsy), Pfizer, Eli Lilly, and AbbVie have CNS divisions but no direct epilepsy product exposure comparable to UCB. The bill's coordination may eventually streamline research, but that is years out and contingent on future appropriations.
Real market data shows UCB (United Community Banks — a bank, NOT the Belgian pharma UCB) is miscoded in the provided data. The ticker in the provided data belongs to United Community Banks (a regional bank), not UCB S.A. (the Belgian pharma), which does not trade on U.S. exchanges as . The Belgian pharma UCB trades OTC as $UCBJY. This creates a significant analytical limitation: the pure-play epilepsy company is not directly captured in the provided market data.
Timeline: The bill is in the earliest legislative stage. It must pass committee, pass both chambers in identical form, and be signed by the President. Given no funding and no controversy, passage probability is moderate but distant. Any market impact requires at minimum a separate appropriations bill, which has not been introduced.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →